Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945552 | 0.90 | MEN1 (0.44) | MEN1KMT2AHTTNPSR1ALDH1A1 | |
| SCHEMBL393821 | 0.87 | ALDH1A1 (0.43) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL392099 | 0.87 | KMT2A (0.51) | ADORA1MEN1KMT2AHTTNPSR1 | |
| SCHEMBL3946879 | 0.83 | PTGS2 (0.59) | PTGS2 | |
| SCHEMBL393814 | 0.82 | ALDH1A1 (0.38) | MAPK13MAPK12MAPK11MAPK14MEN1 | |
| SCHEMBL3942828 | 0.81 | KMT2A (0.49) | MAPK13MAPK12MAPK11MAPK14ADORA1 | |
| SCHEMBL3941272 | 0.81 | KMT2A (0.49) | MAPK13MAPK12MAPK11MAPK14ADORA1 | |
| SCHEMBL395735 | 0.80 | MARS1 (0.43) | KMT2AALDH1A1PTGS2 | |
| SCHEMBL395225 | 0.80 | SLC34A1 (0.42) | MAPK13MAPK12MAPK11MAPK14PTGS2 | |
| SCHEMBL3938949 | 0.79 | MEN1 (0.52) | ADORA1MEN1KMT2AHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101207-B2 | Composition containing medicine extremely slightly soluble in water and method for preparation thereof | KOWA CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1043317-B1 | PYRIDAZINE DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS ACTIVE INGREDIENT | KOWA CO (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-2017266-A1 | Pyridazine derivatives and medicines containing the same as effective ingredients | Kowa Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | KOWA CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-12-01 | — | — | US | disclosed |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | KOWA CO., LTD. (JP) | 2002-09-05 | — | — | US | disclosed |
| US-6348468-B1 | THESE COMPOUNDS HAVE EXCELLENT INHIBITORY ACTIVITY AGAINST INTERLEUKIN-1.BETA. PRODUCTION, IMMUNE SYSTEM DISEASES, INFLAMMATORY DISEASES, ISCHEMIC DISEASES AND THE LIKE. | KOWA CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1043317-A1 | NOVEL PYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Kowa Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208025-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | MAPK13 1158/4885MAPK12 434/4885MAPK11 980/4885 |
| US-20050267113-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IL1R1, IRAK1 | MAPK13 1147/4885MAPK12 448/4885MAPK11 1046/4885 |
| US-20090270399-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | MAPK13 1062/4885MAPK12 355/4885MAPK11 852/4885 |
| US-20050065155-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | MAPK13 1343/4885MAPK12 484/4885MAPK11 1151/4885 |
| US-20040147516-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | MAPK13 962/4885MAPK12 393/4885MAPK11 805/4885 |
| US-20070049595-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | MAPK13 1343/4885MAPK12 484/4885MAPK11 1151/4885 |
| US-20060160804-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, TLR1, IRAK1 | MAPK13 1343/4885MAPK12 484/4885MAPK11 1151/4885 |
| US-20090069332-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | MAPK13 1062/4885MAPK12 355/4885MAPK11 852/4885 |
| US-20020123496-A1 | Novel pyridazine derivatives and medicines containing the same as effective ingredients | IL1B, IRAK1, TLR1 | MAPK13 962/4885MAPK12 393/4885MAPK11 805/4885 |
| US-20080119474-A1 | NOVEL PYRIDAZINE DERIVATIVES AND MEDICINES CONTAINING THE SAME AS EFFECTIVE INGREDIENTS | IL1B, IL1R1, TLR1 | MAPK13 1158/4885MAPK12 434/4885MAPK11 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.